Skip to main content

Table 2 Baseline characteristics and association between dichotomized serum HER2 ECD level and clinicopathologic variables

From: Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

Characteristics

Total group

Subgroup with normal serum HER2 ECD level (≤15.2 ng/ml)

Subgroup with elevated serum HER2 ECD level (>15.2 ng/ml)

P a

 

n

%

n

%

n

%

 

Total patients

2,862

100%

2,736

100%

126

100%

 

Serum HER2 ECD, ng/ml

 Mean ± SD

10.1 ± 9.4

9.3 ± 1.9

27.3 ± 40.4

<0.001b

 Median (range)

9.2 (3.3–427.8)

9.1 (3.3–15.2)

18.5 (15.3–427.8)

 

Age at diagnosis, years

      

0.860b

 Mean ± SD

48.5 ± 9.9

48.5 ± 9.9

48.4 ± 10.3

 

 Median (range)

48 (22–94)

48.0 (22–94)

49.0 (26–88)

 

Age subgroup, years

  ≤ 34

172

6%

162

6%

10

8%

0.100

 35–49

1,510

53%

1,455

53%

55

44%

 

  ≥ 50

1,180

41%

1,119

41%

61

48%

 

Stage

 I/II

2,457

86%

2,376

87%

81

64%

<0.001

 III

405

14%

360

13%

45

36%

 

Tumor size, cm

  ≤ 2

1,676

59%

1,625

59%

51

40%

<0.001

  > 2

1,186

41%

1,111

41%

75

60%

 

Lymph node

 Negative

1,749

61%

1,694

62%

55

44%

<0.001

 Positive

1,113

39%

1,042

38%

71

56%

 

Histologic grade

 1/2

1,787

64%

1,734

65%

53

43%

<0.001

 3

1,025

36%

954

35%

71

57%

 

 Unknown

50

 

48

 

2

  

Nuclear grade

 1/2

1,775

63%

1,730

64%

45

41%

<0.001

 3

1,049

37%

984

36%

65

59%

 

 Unknown

38

 

22

 

16

  

LVI

 Negative

2,095

76%

2,007

76%

88

75%

0.830

 Positive

660

24%

631

24%

29

25%

 

 Unknown

107

 

98

 

9

  

Hormone-receptor status

 Negative

916

32%

831

30%

85

68%

<0.001

 Positivec

1,940

68%

1,899

70%

41

32%

 

 Unknown

6

 

6

 

0

  

Tissue HER2 status

 Negative

2,168

76%

2,146

79%

22

17%

<0.001

 Positived

692

24%

588

21%

104

83%

 

 Unknown

2

 

2

 

0

  

Definitive surgery

      

<0.001

 Conservation

1,781

62%

1,743

64%

38

30%

 

 Mastectomy

1,081

38%

993

36%

88

70%

 

Radiotherapy

 Yes

2,047

72%

1,973

72%

74

59%

0.001

 No

813

28%

761

28%

52

41%

 

 Unknown

2

 

2

 

0

  

Chemotherapy

 Yes

1,852

65%

1,746

64%

106

84%

<0.001

 No

1,007

35%

987

36%

20

16%

 

 Unknown

3

 

3

 

0

  

Anti-HER2 therapy

 Yes

264

9%

211

8%

53

42%

<0.001

 No

2,598

91%

2,525

92%

73

58%

 
  1. aCalculated by chi-square test except where stated otherwise.
  2. bCalculated by t-test.
  3. cEstrogen- and/or progesterone-receptor positive.
  4. dGraded as 3+ on IHC or 2+ on fluorescence in situ hybridization in cases of IHC 2+.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us